欧洲呼吸学会家族性肺纤维化声明
欧洲呼吸学会组建国际多学科专家组,检索1945至2022年文献,就家族性肺纤维化的基因测序适用人群、自然史、检测基因、端粒长度测量证据、常见遗传变异作用、治疗选择及家属筛查随访等八个问题达成共识,为临床管理和未来国际推荐提供基础。
要点
- 家族性肺纤维化存在遗传易感,多个基因突变已被证实可导致肺纤维化。
- 专家组就基因测序适用患者、检测基因、端粒长度测量证据及家属筛查随访达成共识。
- 该声明为家族性肺纤维化患者及家属的临床管理提供框架,尚需前瞻性评估。
核心结论
- 专家组通过文献综述就家族性肺纤维化的基因测序、临床管理和家属筛查达成共识声明。
- 该声明可作为未来前瞻性评估和国际推荐的基础。
研究设计与样本
- 国际多学科专家组(呼吸科医生、遗传学家、儿科医生、病理学家、遗传咨询师、患者代表和图书馆员)组成工作组。
- 工作组检索1945年至2022年的文献并达成共识。
主要发现
- 多个基因突变已被证实可导致肺纤维化,支持遗传易感性。
- 部分国家已将家族性肺纤维化病例的基因测序纳入常规临床实践,但许多中心尚未在间质性肺疾病服务中整合基因测序。
- 目前尚未建立适当的国际共识。
关键数值与推荐
- 专家组就以下问题达成共识:哪些患者可能受益于基因测序和临床咨询。
- 家族性肺纤维化的自然史已知信息。
- 通常检测哪些基因。
- 端粒长度测量的证据。
- 常见遗传变异(多态性)在诊断检查中的作用。
临床怎么用
- 声明为家族性肺纤维化患者及其亲属的基因测序、临床管理和筛查提供参考。
- 可作为未来前瞻性评估和国际推荐的基础。
局限性
- 声明基于文献综述和专家共识,尚需前瞻性评估。
- 目前尚未建立国际共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genetic predisposition to pulmonary fibrosis has been confirmed by the discovery of several gene mutations that cause pulmonary fibrosis. Although genetic sequencing of familial pulmonary fibrosis (FPF) cases is embedded in routine clinical practice in several countries, many centres have yet to incorporate genetic sequencing within interstitial lung disease (ILD) services and proper international consensus has not yet been established. An international and multidisciplinary expert Task Force (pulmonologists, geneticists, paediatrician, pathologist, genetic counsellor, patient representative and librarian) reviewed the literature between 1945 and 2022, and reached consensus for all of the following questions: 1) Which patients may benefit from genetic sequencing and clinical counselling? 2) What is known of the natural history of FPF? 3) Which genes are usually tested? 4) What is the evidence for telomere length measurement? 5) What is the role of common genetic variants (polymorphisms) in the diagnostic workup? 6) What are the optimal treatment options for FPF? 7) Which family members are eligible for genetic sequencing? 8) Which clinical screening and follow-up parameters may be considered in family members? Through a robust review of the literature, the Task Force offers a statement on genetic sequencing, clinical management and screening of patients with FPF and their relatives. This proposal may serve as a basis for a prospective evaluation and future international recommendations.
引用
- Borie R, Kannengiesser C, Antoniou K, et al. European Respiratory Society statement on familial pulmonary fibrosis. Eur Respir J. 2023. PMID: 36549714. doi:10.1183/13993003.01383-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。